GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of anyone else notice tirzepatide kicking in around week 13 — 23 comments in the full submission. View in context.
3.5k
c/tirzepatide·submitted 1 months ago by u/kaia_cabrera

anyone else notice tirzepatide kicking in around week 13

Resultsbranch of 10 comments

anyone else notice tirzepatide kicking in around week 13, logged the same way every week so the comparison is at least internally fair. The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to. It is…

Read the full submission and all 23 comments →

This branch

10 comments, started 1 months ago
u/georgi_chowdhury140 points·1 months ago

SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.

replysharereportpermalink
u/titration_marshalMOD91 points·1 months ago

Removed the conversion table. There is no published equivalence between the two molecules and posting one as fact is exactly the kind of thing that gets copied for years.

replysharereportpermalink
u/incretin_ivypharmacology77 points·1 months ago

SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change.

Not sure about this bit. The GIP arm being real does not tell you that it is what caused your particular week.

replysharereportpermalink
u/crosspost_bot_no54 points·1 months ago

The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.

replysharereportpermalink
u/ewan_marchand33 points·1 months ago

The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.

Saving this one. It is the clearest statement of the stall problem I have read here.

replysharereportpermalink
load more comments (5) →

← back to the whole thread

About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.